Comorbid Social Phobia and Major Depressive Disorder: the Influence of Remission from Depression on Quality of Life and Functioning

Alexander Joseph Steiner, Stephanie Marie Wright, Taylor Kuhn and Waguih William IsHak ()
Additional contact information
Alexander Joseph Steiner: Department of Psychology, California School of Professional Psychology at Alliant International University
Stephanie Marie Wright: Department of Psychology, California School of Professional Psychology at Alliant International University
Taylor Kuhn: University of California Los Angeles
Waguih William IsHak: Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center

Applied Research in Quality of Life, 2017, vol. 12, issue 3, No 11, 719-736

Abstract: Abstract Social phobia (SP) and major depressive disorder (MDD) are frequently concurrent, which negatively affects quality of life (QOL), functioning, and depressive symptom severity. We hypothesized individuals with comorbid SP and MDD (MDD + SP) would have worse treatment outcomes than those with MDD alone (MDDnoSP), but that both groups would have significant responses to treatment, and those who achieved MDD remission would have the best increases in QOL and functioning. We analyzed data for 2280 adults who received citalopram monotherapy in phase 1 of the NIH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Participants (82 MDD + SP and 2198 MDDnoSP) with complete entry and exit scores across QOL, functioning, and depressive symptom severity were examined. MDD remission status following treatment was determined. Patient-reported QOL and functioning scores were classified as within-normal or severely-impaired. No significant between-group differences were observed across all outcomes at entry or exit. Both groups experienced significant improvements in QOL and functioning (all p values .77). Although non-significant, the MDD + SP group was more likely to achieve within-normal scores and MDD remission post-treatment. Findings were interesting as we initially expected the MDD + SP participants to have worse outcomes, yet those with MDD alone had a more chronic course. Regardless, participants who were able to achieve MDD remission post-treatment had significantly better improvements in QOL and functioning. Accordingly, researchers and clinicians should utilize QOL and functioning measures when examining treatment effectiveness, while also considering the role of remission from major depressive disorder on quality of life.

Keywords: Quality of life; Patient-reported outcomes; Social phobia; Major depressive disorder; Comorbidity; Functioning; Remission (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s11482-016-9485-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:ariqol:v:12:y:2017:i:3:d:10.1007_s11482-016-9485-4

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/11482

DOI: 10.1007/s11482-016-9485-4

Access Statistics for this article

Applied Research in Quality of Life is currently edited by Daniel Shek

More articles in Applied Research in Quality of Life from Springer, International Society for Quality-of-Life Studies
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().